title: Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
authors.affiliation: Department of Medical Oncology, Georges François Leclerc Center, Centre de Recherche INSERM 866, Faculté de Médecine, Dijon, France. sladoire@cgfl.fr
authors.forename: Sylvain
authors.initials: S
authors.lastname: Ladoire
authors.forename: Jean Christophe
authors.initials: JC
authors.lastname: Eymard
authors.forename: Sylvie
authors.initials: S
authors.lastname: Zanetta
authors.forename: Grégoire
authors.initials: G
authors.lastname: Mignot
authors.forename: Etienne
authors.initials: E
authors.lastname: Martin
authors.forename: Isabelle
authors.initials: I
authors.lastname: Kermarrec
authors.forename: Eric
authors.initials: E
authors.lastname: Mourey
authors.forename: Frédéric
authors.initials: F
authors.lastname: Michel
authors.forename: Luc
authors.initials: L
authors.lastname: Cormier
authors.forename: François
authors.initials: F
authors.lastname: Ghiringhelli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D003520:Cyclophosphamide; D011239:Prednisolone; D017430:Prostate-Specific Antigen